Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce

Vandana Singh
1 min read
0
In this article:

  • Aligos Therapeutics Inc (NASDAQ: ALGS) announced a portfolio reprioritization, with priorities focused on the rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs.

  • The company also plans to maintain its ongoing NASH oligonucleotide research collaborations with Merck & Co Inc (NYSE: MRK).

  • Additionally, the company plans to complete the ≤48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

  • Also Read: Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud.

  • The reorganization comes with a layoff of around 10% of its staff to extend its cash resources through the end of 2024.

  • In all, there's been a 25% reduction in the overall workforce at Aligos since the beginning of 2022.

  • The company has already initiated Phase 2-enabling activities for the NASH program, including GLP toxicology studies, and it is planning a Phase 2 filing by the end of 2023.

  • COVID-19 program, ALG-097558, is expected to complete Phase 1-enabling activities in H1 2023. The company aims to complete a Phase 1 study evaluating single and multiple ascending doses in healthy volunteers in H2 2023 to enable the start of a Phase 2 study by the end of 2023.

  • Price Action: ALGS shares are down 1.15% at $1.8386 on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories